What Researchers Did
Researchers conducted a comprehensive review of literature from the past decade on hyperbaric oxygen therapy (HBOT) for rheumatic and autoimmune diseases.
What They Found
Hyperbaric oxygen therapy (HBOT) showed an efficacy rate of 87.5%-100% for rheumatic and autoimmune diseases with skin ulcers and a pain relief rate of 87.5%-100% for fibromyalgia syndrome. It also had favorable effects on sensorineural hearing loss and acute macular neuroretinopathy. Mild adverse effects like barotrauma, tinnitus, headache, and claustrophobia were reported in seven studies, all resolving upon discontinuation.
What This Means for Canadian Patients
Canadian patients with rheumatic and autoimmune diseases experiencing complications like skin ulcers or fibromyalgia pain might find hyperbaric oxygen therapy (HBOT) to be a beneficial treatment option. This therapy could offer significant relief for symptoms that are often difficult to manage with conventional treatments.
Canadian Relevance
This review article does not have a direct Canadian connection.
Study Limitations
As a review, this study's findings are dependent on the quality and heterogeneity of the included literature, and specific long-term outcomes were not detailed.